Stocks and Investing Stocks and Investing
Thu, January 2, 2020
Tue, December 31, 2019
Mon, December 30, 2019

Charles Duncan Reiterated (AXSM) at Buy with Increased Target to $125 on, Dec 30th, 2019


Published on 2024-10-26 19:32:12 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Reiterated "Axsome Therapeutics, Inc." (AXSM) at Buy with Increased Target from $104 to $125 on, Dec 30th, 2019.

Charles has made no other calls on AXSM in the last 4 months.



There is 1 other peer that has a rating on AXSM. Out of the 1 peers that are also analyzing AXSM, 0 agree with Charles's Rating of Hold.



This is the rating of the analyst that currently disagrees with Charles


  • Yatin Suneja of "Guggenheim" Maintained at Strong Buy with Increased Target to $158 on, Monday, December 16th, 2019
Contributing Sources